NextCure, Inc. (NXTC)

NASDAQ: NXTC · Real-Time Price · USD
0.4654
-0.0278 (-5.64%)
Apr 30, 2025, 4:00 PM EDT - Market closed
Market Cap 13.03M
Revenue (ttm) n/a
Net Income (ttm) -55.65M
Shares Out 28.01M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 246,728
Open 0.4990
Previous Close 0.4932
Day's Range 0.4569 - 0.4990
52-Week Range 0.2240 - 1.8200
Beta 0.89
Analysts Strong Buy
Price Target 3.50 (+652.04%)
Earnings Date May 13, 2025

About NXTC

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as w... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2019
Employees 43
Stock Exchange NASDAQ
Ticker Symbol NXTC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for NXTC stock is "Strong Buy." The 12-month stock price forecast is $3.5, which is an increase of 652.04% from the latest price.

Price Target
$3.5
(652.04% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-...

27 days ago - GlobeNewsWire

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...

7 weeks ago - GlobeNewsWire

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-...

3 months ago - GlobeNewsWire

NextCure Announces Acceptance of IND Application for LNCB74

LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed fo...

5 months ago - GlobeNewsWire

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c...

5 months ago - GlobeNewsWire

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c...

5 months ago - GlobeNewsWire

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

BELTSVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-...

6 months ago - GlobeNewsWire

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c...

6 months ago - GlobeNewsWire

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c...

7 months ago - GlobeNewsWire

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-...

8 months ago - GlobeNewsWire

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c...

11 months ago - GlobeNewsWire

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-cl...

11 months ago - GlobeNewsWire

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-c...

1 year ago - GlobeNewsWire

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) --  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in...

1 year ago - GlobeNewsWire

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74 Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74

1 year ago - GlobeNewsWire

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-...

1 year ago - GlobeNewsWire

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-...

1 year ago - GlobeNewsWire

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

BELTSVILLE, Md. – March 21, 2024, March 21, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-c...

1 year ago - GlobeNewsWire

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici...

1 year ago - GlobeNewsWire

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure Provides Year-End Clinical Pipeline Updates

BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

BELTSVILLE, Md., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire